Lamin A/C and the heart: how LMNA mutations cause cardiomyopathy
Official title: Comparative study of gene regulatory and structural mechanisms in Lamin-related cardiomyopathy
Funded at Cincinnati Childrens Hosp Med Ctr · NIH-11401202 · Data updated 2026-11-12
This grant tests two ideas about why LMNA mutations lead to dilated cardiomyopathy in adults, with goals that could point to new ways to treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | August 27, 2025 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $496,085 |
| NIH project number | 5R01HL176565-02 |
| Project ID | NIH-11401202 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with LMNA-related cardiomyopathy or related cardiac conditions; those who could contribute tissue samples or patient-derived cells.
✕Less likely to help
Patients without LMNA mutations or cardiac conditions are unlikely to benefit directly.
What this research studies
Lamin A/C helps keep heart cell nuclei stable and regulate genes. The study compares whether disease comes from changes in gene regulation or from a weaker nuclear envelope, or a combination of both. Researchers will use heart cells to see how LMNA mutations affect chromatin and nuclear structure during maturation from fetal to adult stages. The aim is to clarify which mechanism drives LMNA-related cardiomyopathy and how they might interact, guiding future therapies.
Why it matters
Potential benefit: Understanding the mechanism could lead to targeted treatments for LMNA-related cardiomyopathy.
How similar studies have gone: Prior work has suggested gene regulation and nuclear structure both play roles, but direct comparison in LMNA-DCM is novel.
Where this research is happening
-
Cincinnati Childrens Hosp Med Ctr
Cincinnati, United States Active
Researchers
- Principal investigator: Ikegami, Kohta — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Ikegami, Kohta
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.